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Abstract
Background:  Ex-vivo chemosensitivity tests that measure cell death induction may predict
treatment outcome and, therefore, represent a powerful instrument for clinical decision making in
cancer therapy. Such tests are, however, work intensive and, in the case of the DiSC-assay, require
at least four days. Induction of apoptosis is the mode of action of anticancer drugs and should,
therefore, result in the induction of caspase activation in cells targeted by anticancer therapy.
Methods:  To determine, whether caspase activation can predict the chemosensitivity, we
investigated enzyme activation of caspase-3, a key executioner caspase and correlated these data
with chemosensitivity profiles of acute myeloid leukemia (AML) blasts.
Results: There was, however, no correlation between the ex-vivo chemosensitivity assessed by
measuring the overall rates of cell death by use of the DiSC-assay and caspase-3 activation.
Conclusion: Thus, despite a significant reduction of duration of the assay from four to one day,
induction of apoptosis evaluated by capase-3 activity does not seem to be a valid surrogate marker
for chemosensitivity.
Background
Cytogenetic abnormalities, age, initial leucocyte count
and P-glycoprotein expression are examples of widely
accepted prognostic factors in acute myeloid leukemia [1-
5]. However, the prognosis of an individual patient may
still not accurately be determined by these factors. The ex-
vivo chemosensitivity profile may help to predict the indi-
vidual response to therapy and, more importantly, to
individualize the treatment and to identify new agents [6-
8].
Many ex-vivo chemosensitivity assays have been investi-
gated for over 40 years. The clonogenic assay is a long
term assay but technical drawbacks and the long culturing
time have limited the clinical use of the method [9,10].
Most assays used today are short term total cell kill assays,
however, the methods to determine viable cells after incu-
bation with cytotoxic agents vary greatly between direct
evaluation of the cells and, in the vast majority, indirect
evaluation using different surrogate markers. The differen-
tial staining cytotoxicity assay (DiSC) uses microscopic
evaluation of dye exclusion in viable cells [11,12]. In the
MTT assay, surviving cells reduce the methyl-thiazol-tetra-
zolium (MTT) into highly colored formazan which can be
quantified by spectrophotometry [13-15]. Other assays
have used fluorescein diacetate (FMCA) or cellular ATP
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content as a surrogate marker of cell viability [16,17]. All
these assays mentioned above are based on essentially the
same culturing procedures in terms of incubating fresh
leukemic cells with cytotoxic agents over a period of four
to five days. A shorter duration of assays, however, may be
useful to obtain ex-vivo chemosensitivity profiles prior
the onset of treatment and would allow to individualize
the therapy in most patients.
It is generally accepted that cytotoxic drugs eliminate
malignant cells by inducing apoptosis (programmed cell
death) [18,19]. This process starts, as it was shown in
hematopoietic tumor cell lines, within hours of exposure
to cytotoxic drugs [20]. Thus, quantification of a surrogate
marker of apoptosis might be a suitable method for a fast
ex-vivo chemosensitivity assay. The appearance of phos-
pholipids like phosphatidylserine at the cell surface is a
common marker for apoptosis which can be detected by
Annexin V using flow cytometry [21,22]. Apoptosis may
also be quantified by changes of the mitochondrial elec-
trochemical transmembrane potential using DiOC6 or JC-
1 [21,23], by detection of DNA- respectively nuclear-frag-
mentation using the TdT-assay [23], gel-electrophoresis or
acridine orange [21,24-26]. Further apoptotic markers are
the cleaved forms of poly (ADP-ribose) polymerase
(PARP) and caspase-3 which both are detectable by spe-
cific antibodies [24,25,27-29].
Most of these methods allow some grade of automation
and a reasonable number of samples to be processed,
which is needed for the clinical use of an ex-vivo chemo-
sensitivity assay as well as for the identification of new
agents. A development allowing more automation and
larger sample sizes might be the detection of activated cas-
pase-3, the main effector caspase in the apoptotic enzyme
cascade, by using fluorogenic substrates and detection of
enzyme activation in microplate readers [30]. To evaluate
the usefulness and accuracy of such a procedure, we inves-
tigated the ex-vivo chemosensitivity assessed by measur-
ing caspase-3 activation and, also, compared these data to
results obtained by DiSC assay in AML blasts.
Methods
Patient samples
Bone marrow (BM) or peripheral blood (PB) were taken
from adult patients with acute myeloid leukemia (AML)
with informed consent during routine diagnostic BM aspi-
ration and/or phlebotomy before treatment was started.
Samples were collected in heparinized tubes from patients
treated at our institution.
Cell lines
For establishing the caspase-3 assay the AML cell lines
THP-1, HEL and KG-1 were used.
Drugs
Drugs were dissolved according to manufacturers' instruc-
tions and diluted in RPMI 1640 culture medium (Gibco,
Paisley, UK). In order to induce cytotoxicity levels ex vivo
comparable with those induced in vivo, the drugs were
used at concentrations encompassing the range of clini-
cally relevant plasma levels, as previously reported [31].
Cytarabine (Ara-cell™, cell-pharm, Hannover, Germany)
was used at final concentrations in the range from 0.06
µg/ml to 5 µg/ml in the DiSC-Assay and from 0.06 to 20
µg/ml in the caspase-3 assay. Daunorubicin (Daunoblas-
tin™, Pharmacia, Erlangen, Germany) was tested at final
concentrations ranging from 0.008 µg/ml to 2 µg/ml and
from 0.008 µg/ml to 5 µg/ml, mitoxantrone
(Novantron™, Lederle, Münster, Germany) from 0.006
µg/ml to 0.5 µg/ml and from 0.006 µg/ml to 20 µg/ml in
the DiSC-assay and the caspase-3 assay, respectively. The
drugs were tested in duplicate samples at 5 different con-
centrations in the DiSC-Assay and in triplicate samples at
six different concentrations in the caspase-3 assay.
Differential Staining Cytotoxicity (DiSC)-Assay
The DiSC-assay was performed as previously described
with minor modifications [11,32-34]. After density gradi-
ent isolation 105 fresh leukemic cells were resuspended in
RPMI 1640 medium (Life Technologies, Germany) con-
taining 10% heat-inactivated fetal calf serum (Biochrom,
Germany) and penicillin-streptomycin (Life Technolo-
gies, Germany). Cells were incubated either without (con-
trol samples) or with added cytotoxic drug in a total
volume of 200 µl (37°C, humidified 5% CO2) for 96
hours. After the incubation 1% fast-green and 0.5%
nigrosin (Sigma Aldrich Chemie, Taufkirchen, Germany),
including fixed duck erythrocytes as an internal standard,
were added to each tube. Cells were transferred to colla-
gen surfaced microscope slides by cytocentrifugation, air-
dried and counterstained with May-Grünwald-Giemsa
stain (Sigma Aldrich Chemie). Subsequent evaluation of
slides by light microscopy facilitated the determination of
drug efficacy at each drug concentration compared with
controls.
Caspase-3 activity assay
For measuring the activation of the caspase-3 we used the
fluorometric assay TIA (Test for Induced Apoptosis) Prod-
uct No. CDC_101 Evotec technologies, subsequently
called Casp3-test (Evotec Analytical Systems, Erkrath, Ger-
many). This assay employs the peptide substrate DEVD-
AMC. 105 ficoll isolated mononuclear cells were incu-
bated without (control samples) or with added cytotoxic
drug in a total volume of 100 µl (37°C, humidified 5%
CO2) for 16 hours. Afterwards, cell lysis was performed by
adding 10 µl of lysis-solution (Evotec) and 90 µl lysis
buffer (Evotec) to each well and incubating the suspen-
sion for one hour at room temperature in the dark on aBMC Cancer 2005, 5:60 http://www.biomedcentral.com/1471-2407/5/60
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shaker. For fluorometric detection of caspase-3 activity
1% (v/v) substrate DEVD covalently linked to the fluoro-
genic dye (7-amino-4-methyl coumarin, AMC) was
added. Upon cleavage by caspase-3 free dye as an indica-
tor for cumulated caspase-3 activity was detected using a
fluorescence microplate reader (SPECTRAFluor, Tecan,
Grödig/Salzburg, Austria) with a 360 nm excitation and a
465 nm emission filter for 30 to 60 minutes.
Data analysis
For the DiSC assay logistic curves were fitted to the cell
count survival data; the logit of survival probability was
taken to be linear with respect to the logarithm of drug
concentration [8,34,35]. LC90-doses, that is, the concen-
tration of drug to produce a 90% reduction in cell survival
compared with control cells, were determined by calculat-
ing the log dose at which the fitted survival probability
was equal to 0.1. As LC90-results are log normal, all LC90-
values were logged (base 10) before calculation of
median, ranges of concentrations and statistical tests.
Established analyzing procedures for ex-vivo chemosensi-
tivity assays assume that the minimum and the maximum
drug-effects are defined. In case of enzymes like the cas-
pases the in-vivo maximum activity in live cells cannot be
reliably obtained. Therefore, an analyzing procedure to
describe the relationship between drug concentration and
caspase activation had to be developed for the Casp3-test
and is presented as part of the results. For comparison




In this study, we examined 42 AML-specimens. Patient
characteristics are shown in Table 1. The diagnosis and
classification of AML was confirmed by central review of
bone marrow slides, at our institution patients were
treated according to treatment protocols of the AML-
Cooperative Group (AMLCG, Germany).
Evaluation of caspase-3 assay (Casp3-test)
Before using the Casp3-test for the assessment of the ex-
vivo drug sensitivity an analyzing procedure had to be
developed. With increasing drug concentrations we
observed an increasing fluorescence signal following an S-
shaped curve for the caspase-3 activity. This dependence
of fluorescence upon the concentration of a cytotoxic drug
with the appearance of a saturation behavior corresponds
to kinetics described by the Michaelis-Menten equation.
The base-level of fluorescence was integrated into the
Michaelis-Menten equation by adding a constant "CutOff
" as follows:
V = CutOff + Vmax*[S]/([S]+Km)
with V being the gradient of fluorescence, Vmax being the
maximum gradient of fluorescence, [S] the drug concen-
tration, CutOff the base-level of fluorescence and Km
being the Michaelis constant describing the drug concen-
tration at half maximum rate of reaction (Figure 1). The
Km served as a measure for the cytotoxic efficacy of the
chemotherapeutic agents.
Table 1: Patient characteristics
Patients diagnosed with AML, no 42
Age [years]: median (range) 45 (19 – 73)
Female/male ratio, no 16/26
Successful DiSC-assays, no (%) 37/42 (88%)
Successful Casp3-tests, no (%) 42/42 (100%)
Successful single drug tests, no (%) 116/126 (92%)
DiSC-assay / Casp3-test correlation, no (%) 37/42 (88%)
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For defining an optimal incubation period to allow time
for all drugs studied to exert their apoptotic effect and,
also, to find stable caspase-3 activity rates we performed
time course experiments. The AML cell lines HEL, THP-1
and KG-1 were incubated with daunorubicin (0.03 – 5 µg/
ml) and cytarabine (0.19 – 20 µg/ml). The incubation was
stopped after every two hours up to 24 hours. Plotting the
fluorescence signal in dependence upon incubation time,
maximum values were observed at different time points
corresponding to different drug concentrations. Usually,
the highest drug concentrations achieved their maximum
of relative fluorescence (compared to controls) after 8 to
12 hours of incubation in contrast to lower concentra-
tions with 12 to 14 hours. Generally, higher fluorescence
levels were obtained by higher drug concentrations.
Stability of Km
The Km as a marker for the cytotoxic efficacy of a specific
drug was determined according to the Michaelis-equation
as described above. Stable Km-values were achieved during
incubation with daunorubicin within 14 hours and with
cytarabine within 12 hours (Figure 2). In order to have
reliably stable rates of apoptosis we chose an incubation
time of 16 hours.
Ex-vivo chemosensitivity by the DiSC-assay
In 37 of 42 AML samples (88%) the DiSC-assay was suc-
cessfully performed. In 5 cases the assay failed due to bac-
terial contamination. All chemotherapeutic drugs tested –
ara-C, daunorubicin and mitoxantrone – induced cell
death in a dose-dependent manner (Figure 1). The sensi-
tivities of the AML cells expressed as LC90s showed varia-
bility between the patients from as much as 22-fold below
(for ara-C) to 105-fold above (also for ara-C) the median
value (Table 2). For each drug, a range of sensitivities was
observed, ranging from very sensitive to very resistant
[11,36]. These individual patient drug sensitivity profiles
reflect the patient heterogeneity seen in the clinic [37]. If
more than 90% of the tumor cells were already killed by
the lowest drug concentration, the LC90-value was set
equal to the corresponding lowest drug concentration
[13]. This was observed in seven cases after incubation
with cytarabine.
Example of a typical dose-response curve received by the  Casp3-test (a) and the DiSC-assay Figure 1
Example of a typical dose-response curve received by the 
Casp3-test (a) and the DiSC-assay (b) in leukemic cells from 
a patient with AML after incubation with daunorubicin. FU = 





















































Average Km-values of daunorubicin and incubation time in  the cell lines HEL, THP-1 and KG-1 Figure 2
Average Km-values of daunorubicin and incubation time in 
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Ex-vivo chemosensitivity by the Casp3-test
The Casp3-test was successful in all 42 AML samples in
terms of measurable caspase activity. But as far as the var-
ious cytotoxic drugs – ara-C, daunorubicin and mitox-
antrone – are concerned apoptosis could be demonstrated
in a dose-dependent manner only in a subset of 116 of
126 tests (92%) (Figure 1). The sensitivities of the AML
blasts expressed as Km showed extreme variability between
the patients from as much as 40-fold below (for daunoru-
bicin) to 6,3 × 108-fold above (for ara-C) the median
value (Table 2). In 14 cases Km-values were less than the
lowest concentration of ara-C used in the assay, hence the
Km-values was set equal to the lowest ara-C concentration
tested in these cases.
Comparison between DiSC-assay and Casp3-test
Both assays were simultaneously performed on each of
the 42 AML samples. Correlation between the two tests
was possible for cytarabine in 33 cases, for daunorubicin
in 36 cases and for mitoxantrone in 33 cases.
For each drug tested the Km-values by the Casp3-test
showed an extreme variability as compared to the LC90-
values by the DiSC-assay, although the median values
were quite similar (Table 2). LC90-values did not correlate
with corresponding Km-values of cytarabine (R2 = 0.38, p
= 0.491), daunorubicin (R2 = 0.001, p = 0.964) or mitox-
antrone (R2 = 0.005, p = 0.544) according to the regres-
sion after Spearman-Rho. The associations of LC90-values
with Km-values of the three drugs are shown in Figure 3.
Discussion
The major goal of this study was to determine whether the
ex-vivo drug resistance in fresh leukemic cells from
patients with AML is reliably assessed by a short-time
apoptosis-assay that measures caspase-3 activation. To
this end, we compared the Casp3-test with established
methods like the differential staining cytotoxicity (DiSC)-
assay that measures reliably the overall rate of cell death
induced by anticancer drugs [6,8,11,34,37,38]. The cyto-
toxic drugs cytarabine, daunorubicin and mitoxantrone,
commonly used in the treatment of AML were tested in
both assays.
In the Casp3-test, the activation of proteases that recog-
nize the DEVD peptide motif (DEVD-ases), especially cas-
pase-3 was detected by measuring a fluorescence signal
generated by a fluorogenic dye upon cleavage by caspase-
3. It has been repeatedly demonstrated that apoptosis usu-
ally is the dominant mode of tumor cell death promoted
by chemotherapy [19,39,40], and caspase-3 is a major
effector protease in this process [41-44]. Our results indi-
cate, however, that levels of caspase-3 activation, i.e.
DEVD-ases, do not correlate with sensitivity or resistance
to commonly employed anticancer drugs in AML blasts.
Even though apoptosis is the main pathway for drug-
induced cell death caspase-3 activities fail to predict the
response to chemotherapy as determined by measuring
ex-vivo chemosensitivity by the DiSC-assay. There was no
association between LC90-values (DiSC-assay) and corre-
sponding Km-values (Casp3-test) of cytarabine (p =
0.491), daunorubicin (p = 0.964) or mitoxantrone (p =
0.544).
The DiSC-assay measures total cell death and, therefore,
integrates apoptotic and non-apoptotic death induced by
chemotherapy. Moreover, the DiSC-assay was shown to
identify response to therapy and also long-term survival in
various hematological neoplastic diseases [8,35]. This
assay has been extensively evaluated in B-CLL, AML and,
also, ALL [8,11,36-38,45]. In a large series of AML
patients, we have recently shown an overall predictive
accuracy for the DiSC-assay of 98.2% concerning treat-
ment response and proofed the ex-vivo chemosensitivity
evaluated by the DiSC-assay as one of the strongest prog-
nostic factors [34]. For the DiSC-assay, it has also been
demonstrated that it runs more reliable than colony-form-
ing assays that measure clonogenic growth and that
results obtained by DiSC-assay are equivalent to both, the
colony-forming assay and the colorimetric MTT-assay
[32,36]. Based on this background, the DiSC-assay serves
as an established standard method to evaluate the individ-
ual ex-vivo chemosensitivity and, also, as an appropriate
reference method to evaluate and establish new ex-vivo
chemosensitivity assays. Furthermore, the DiSC-assay has
also been used to study various parameters influencing
the apoptotic process [46,47].
Table 2: Median LC90- (DiSC-assay) and Km-values (Casp3-test) for cytarabine, daunorubicin and mitoxantrone (range).
Drug LC90 (µg/ml) Km (µg/ml)
Cytarabine 1.40 (0.06 – 147.44) 0.270 (0.062 - >20)
Daunorubicin 0.63 (0.2 – 1.59) 0.443 (0.011 - >5)
Mitoxantrone 0.235 (0.02 – 3.34) 0.222 (0.007 - >20)BMC Cancer 2005, 5:60 http://www.biomedcentral.com/1471-2407/5/60
Page 6 of 8
(page number not for citation purposes)
Therefore, due to the lack of correlation between the
Casp3-test and the DiSC-assay it must be concluded that
the Casp3-test is not equivalent to the DiSC-assay and,
consequently, not appropriate for the assessment of the
individual ex-vivo chemosensitivity and the identification
of new agents. This observation may be due to the test-sys-
tem itself, but it seems more likely that it is due to the
methodology of the Casp3-test to assess chemosensitivity.
Most established ex-vivo chemosensitivity assays measure
total apoptotic cell death after all drugs tested have
exerted their apoptotic effect. In contrast, determination
of caspase-3 activation only reflects the apoptosis at a sin-
gle time. However, total apoptotic cell death is the result
of all apoptotic processes which occur during the whole
incubation time of 96 h in the DiSC assay allowing
enough time for all drugs studied to exert their apoptotic
effect. It becomes clear that the intensity of apoptosis at
one time point does not necessarily represent the intensity
of all apoptotic processes. Moreover, anticancer drugs
may also induce caspase-independent cell death and this
could be neglected when only caspase-3 activities are
determined [26]. It might be argued that 16 hours of incu-
bation with cytotoxic agents in fresh leukemic cells may
be too short for the evaluation of caspase-3 activity, but in
all cell line experiments Km-values were found stabilized
within 14 hours. Additionally, Km-values could be calcu-
lated in 92% of the Casp3-tests done on patient material,
and the median Km-values were comparable with median
LC90-values of the DiSC-assay implicating an adequate
incubation period.
Conclusion
In conclusion, the use of a caspase-3 activity test for the
assessment of the ex-vivo chemosensitity does not appear
to be suitable for the prediction of drug responses.
Therefore, established tests like the DiSC-assay or the
MTT-assay are still the best choice for predicting chemo-
sensitivities of cancer cells.
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